Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Announces Special Stockholder Meeting
17. Januar 2025 17:24 ET | Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
U.S. Oral Solid Dosage Contract Manufacturing Market
United States Oral Solid Dosage Contract Manufacturing Market Set to Reach $11.70 Billion by 2029
09. Januar 2025 11:01 ET | Research and Markets
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "United States Oral Solid Dosage Contract Manufacturing Market, By Region, Competition, Forecast & Opportunities, 2019-2029F" report has been added...
Global High Potency API Contract Manufacturing Market
Growth Trends in the High Potency API Contract Manufacturing Market, Forecast to 2035 - Why Pharma Giants are Turning to CMOs for High-Potency API Production
08. Januar 2025 10:14 ET | Research and Markets
Dublin, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The "High Potency API Contract Manufacturing Market by Product, Synthesis, Application, Dosage Form, End User and Region" report has been added to ...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
07. Januar 2025 09:00 ET | Lifecore Biomedical, Inc.
Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE)...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
06. Januar 2025 16:05 ET | Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update
02. Januar 2025 16:05 ET | Lifecore Biomedical, Inc.
-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- -- Strengthened Balance Sheet with Financing Raising Approximately $24.3...
22157.jpg
Contract Pharmaceutical Dose Manufacturing Industry Research: Composition, Size, Market Share and Outlook for GLP-1 Receptor Agonist Products
23. Dezember 2024 10:18 ET | Research and Markets
Dublin, Dec. 23, 2024 (GLOBE NEWSWIRE) -- The "Contract Pharmaceutical Dose Manufacturing Industry: Composition, Size, Market Share and Outlook - 2024 Edition" report has been added to ...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
19. Dezember 2024 16:05 ET | Lifecore Biomedical, Inc.
CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
19. Dezember 2024 07:00 ET | Lifecore Biomedical, Inc.
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial Lifecore to Leverage Differentiated Capabilities and...
sns insider pvt ltd.png
Global CMO/CDMO Market to Reach USD 38.87 Billion by 2032, Driven by Rising Demand for Outsourced Drug Manufacturing | Research by SNS Insider
12. Dezember 2024 08:00 ET | SNS Insider pvt ltd
Austin, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CMO/CDMO Market Size Analysis: “According to SNS Insider, the CMO/CDMO Market reached USD 23.32 billion in 2023 and is anticipated to grow up to USD 38.87...